Inhibikase Therapeutics (IKT) Net Cash Flow Growth (3y) (2023 - 2026)
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Net Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -8.34% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 36.60% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -35.85% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 106.37% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 67.39% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.55% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 52.78% |
| 10 | Inhibikase Therapeutics | 435.56 Mn | 276.54 Mn | - | -107.64% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -107.64% |
| Mar 31, 2026 | -202.71% |
| Dec 31, 2025 | 315.57% |
| Sep 30, 2025 | -14.31% |
| Jun 30, 2025 | 43.87% |
| Mar 31, 2025 | 82.67% |
| Dec 31, 2024 | 149.70% |
| Sep 30, 2024 | -2.97% |
| Jun 30, 2024 | -73.00% |
| Mar 31, 2024 | -16.18% |
| Dec 31, 2023 | -34.05% |
| Sep 30, 2023 | 1,056.18% |
| Jun 30, 2023 | -626.05% |
| Mar 31, 2023 | -747.36% |